July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapies funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares ’ cancer immunotherapy

Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring immunotherapy

September 2022 Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy

Therefore, GPCRs are potential targets for cancer immunotherapy. progress of clinical trials of GPCR-targeted drugs for cancer treatment, which may be combined with immunotherapy shed light on the mechanisms underlying tumor progression and provide a novel perspective on cancer immunotherapy Authors Guang-Hong Qiu, Bin Yu, Mei Ma Tags GPCRs , cancer immune checkpoints , cancer immunotherapy

GPCRs in Oncology and Immunology The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy restricted Gαs signaling and show that a Gαs-PKA signaling axis promotes CD8+ T cell dysfunction and immunotherapy that Gαs-GPCRs are druggable immune checkpoints that might be targeted to enhance the response to ICB immunotherapies

GPCR Retreat Program < Back to schedule G Proteins and GPCRs in Cancer: Novel Precision Targeted and Immunotherapies precision cancer treatments, and to identify novel multimodal strategies to enhance the response to cancer immunotherapies